A citation-based method for searching scientific literature

Felipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Virginia Arrazubi, Raquel Hernandez, Juana M Cano, Ana Custodio, Carles Pericay Pijaume, Gema Aguado, Nieves Martínez Lago, Manuel Sánchez Cánovas, Diego Cacho Lavin, Laura Visa, Alba Martinez-Torron, Aranzazu Arias-Martinez, Flora López, M Luisa Limón, Rosario Vidal Tocino, Ana Fernández Montes, Maria Alsina, Paola Pimentel, Pablo Reguera, Alfonso Martín Carnicero, Avinash Ramchandani, Mónica Granja, Aitor Azkarate, Marta Martín Richard, Olbia Serra, Carolina Hernández Pérez, Alicia Hurtado, Aitziber Gil-Negrete, Tamara Sauri, Patricia Morales Del Burgo, Javier Gallego. Gastric Cancer 2021
Times Cited: 4







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
75

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
Paula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, Ana Custodio, Juana Maria Cano, Alejandra Lacalle, Isabel Echavarria, Ismael Macias, Monserrat Mangas, Laura Visa,[...]. Br J Cancer 2017
55
50

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, Maria Luisa Sánchez Lorenzo, Javier Gallego Plazas, Ana Custodio, Raquel Hernández, Marcelo Garrido, Teresa García, Isabel Echavarría, Juana María Cano,[...]. Gastric Cancer 2017
17
50

External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martínez de Castro, Ana Custodio, Carles Pericay Pijaume, Raquel Hernandez, Gema Aguado, Natalia Castro Unanua, Juana María Cano, Flora López,[...]. Gastric Cancer 2021
6
50

Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry.
David Zaragoza-Huesca, Pedro Garrido-Rodríguez, Paula Jiménez-Fonseca, Eva Martínez de Castro, Manuel Sánchez-Cánovas, Laura Visa, Ana Custodio, Ana Fernández-Montes, Julia Peñas-Martínez, Patricia Morales Del Burgo,[...]. Biomedicines 2022
3
66

Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries.
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Javier Gallego, Pavlos Msaouel. Cancer Invest 2022
7
50

Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer.
Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Marcelo Garrido, Ana Custodio, Raquel Hernandez, Alejandra Lacalle, Juana María Cano, Gema Aguado, Eva Martínez de Castro, Felipe Alvarez Manceñido,[...]. Thromb Haemost 2019
15
50

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
Almudena Cotes Sanchís, Javier Gallego, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana María Cano, Gema Aguado, Ismael Macias, Carlos Lopez, Flora López,[...]. PLoS One 2020
10
50

Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.
Laura Visa, Paula Jiménez-Fonseca, Elena Asensio Martínez, Raquel Hernández, Ana Custodio, Manuel Garrido, Antonio Viudez, Elvira Buxo, Ignacio Echavarria, Juana María Cano,[...]. J Geriatr Oncol 2018
11
50

Chemotherapy for advanced gastric cancer.
Anna Dorothea Wagner, Nicholas Lx Syn, Markus Moehler, Wilfried Grothe, Wei Peng Yong, Bee-Choo Tai, Jingshan Ho, Susanne Unverzagt. Cochrane Database Syst Rev 2017
377
50

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López,[...]. Ther Adv Med Oncol 2021
3
66

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry.
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Isabel Echavarria, Manuel Sánchez Cánovas, Gema Aguado, Javier Gallego, Ana Custodio, Raquel Hernández, Antonio Viudez, Juana María Cano,[...]. Eur J Surg Oncol 2018
31
50

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.
A Custodio, A Carmona-Bayonas, P Jiménez-Fonseca, M L Sánchez, A Viudez, R Hernández, J M Cano, I Echavarria, C Pericay, M Mangas,[...]. Br J Cancer 2017
38
50

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto,[...]. J Natl Compr Canc Netw 2016
17
50

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
A Carmona-Bayonas, P Jiménez-Fonseca, A Custodio, M Sánchez Cánovas, R Hernández, C Pericay, I Echavarria, A Lacalle, L Visa, A Rodríguez Palomo,[...]. Gastric Cancer 2018
14
50


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
401
50

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
865
50

Risk factors for stomach cancer: a systematic review and meta-analysis.
Jalal Poorolajal, Leila Moradi, Younes Mohammadi, Zahra Cheraghi, Fatemeh Gohari-Ensaf. Epidemiol Health 2020
69
25

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Eric Van Cutsem, Vladimir M Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, Corrado Boni, Adriano Rodrigues, Miguel Fodor, Yee Chao, Edouard Voznyi,[...]. J Clin Oncol 2006
25

Influence of sex on the survival of patients with esophageal cancer.
Pierre Bohanes, Dongyun Yang, Ruchika S Chhibar, Melissa J Labonte, Thomas Winder, Yan Ning, Armin Gerger, Léonor Benhaim, David Paez, Takeru Wakatsuki,[...]. J Clin Oncol 2012
87
25


Sex and gender reporting in global health: new editorial policies.
Sanne A E Peters, Robyn Norton. BMJ Glob Health 2018
26
25

Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use.
Shirin Heidari, Thomas F Babor, Paola De Castro, Sera Tort, Mirjam Curno. Res Integr Peer Rev 2016
409
25

Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.
Linda Lee, Winson Y Cheung, Esther Atkinson, Monika K Krzyzanowska. J Clin Oncol 2011
139
25

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Joseph M Unger, Riha Vaidya, Kathy S Albain, Michael LeBlanc, Lori M Minasian, Carolyn C Gotay, N Lynn Henry, Michael J Fisch, Shing M Lee, Charles D Blanke,[...]. J Clin Oncol 2022
21
25

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.
B C Özdemir, S Oertelt-Prigione, A A Adjei, S Borchmann, J B Haanen, A Letsch, O Mir, A Quaas, R H A Verhoeven, A D Wagner. Ann Oncol 2022
5
25

Capecitabine and oxaliplatin for advanced esophagogastric cancer.
David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman. N Engl J Med 2008
25

Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Alice Chen, Hilary Wright, Hawi Itana, Merina Elahi, Ayomide Igun, Guoxing Soon, Anne R Pariser, Emmanuel O Fadiran. J Womens Health (Larchmt) 2018
23
25

Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.
Julita Machlowska, Jacek Baj, Monika Sitarz, Ryszard Maciejewski, Robert Sitarz. Int J Mol Sci 2020
254
25

Reporting Sex, Gender, or Both in Clinical Research?
Janine Austin Clayton, Cara Tannenbaum. JAMA 2016
232
25


Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
25

Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
Berna C Özdemir, Chantal Csajka, Gian-Paolo Dotto, Anna Dorothea Wagner. J Clin Oncol 2018
67
25

Gender medicine and oncology: report and consensus of an ESMO workshop.
A D Wagner, S Oertelt-Prigione, A Adjei, T Buclin, V Cristina, C Csajka, G Coukos, U Dafni, G-P Dotto, M Ducreux,[...]. Ann Oncol 2019
68
25

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival.
Anouk Rijken, Robin J Lurvink, Misha D P Luyer, Grard A P Nieuwenhuijzen, Felice N van Erning, Johanna W van Sandick, Ignace H J T de Hingh. J Clin Med 2021
8
25

Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Avani Athauda, Matthew Nankivell, Ruth E Langley, Derek Alderson, William Allum, Heike I Grabsch, Naureen Starling, Ian Chau, David Cunningham. Eur J Cancer 2020
16
25

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study.
Willemieke P M Dijksterhuis, Marianne C Kalff, Anna D Wagner, Rob H A Verhoeven, Valery E P P Lemmens, Martijn G H van Oijen, Suzanne S Gisbertz, Mark I van Berge Henegouwen, Hanneke W M van Laarhoven. J Natl Cancer Inst 2021
10
25

Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
Michael Davidson, Anna Dorothea Wagner, Kyriakos Kouvelakis, Henry Nanji, Naureen Starling, Ian Chau, David Watkins, Sheela Rao, Clare Peckitt, David Cunningham. Eur J Cancer 2019
24
25

Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
Anya N A Milne, Ralph Carvalho, Folkert M Morsink, Alex R Musler, Wendy W J de Leng, Ari Ristimäki, G Johan A Offerhaus. Mod Pathol 2006
76
25

Sex/gender reporting and analysis in Campbell and Cochrane systematic reviews: a cross-sectional methods study.
Jennifer Petkovic, Jessica Trawin, Omar Dewidar, Manosila Yoganathan, Peter Tugwell, Vivian Welch. Syst Rev 2018
17
25

Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017.
Lixia Lou, Linyan Wang, Yaoyi Zhang, Guofeng Chen, Lele Lin, Xiaoli Jin, Yi Huang, Jian Chen. BMJ Open 2020
29
25

Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer.
Hae Won Kim, Jie-Hyun Kim, Beom Jin Lim, HyunKi Kim, Hoguen Kim, Jae Jun Park, Young Hoon Youn, Hyojin Park, Sung Hoon Noh, Jong Won Kim,[...]. Ann Surg Oncol 2016
44
25


Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Philipp Müller, Matthias Kreuzaler, Tarik Khan, Daniela S Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Nitz, Oleg Gluz,[...]. Sci Transl Med 2015
193
25

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
John Stagg, Sherene Loi, Upulie Divisekera, Shin Foong Ngiow, Helene Duret, Hideo Yagita, Michele W Teng, Mark J Smyth. Proc Natl Acad Sci U S A 2011
330
25

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
Ian Chau, Charles S Fuchs, Atsushi Ohtsu, Afsaneh Barzi, Astra M Liepa, Zhanglin Lin Cui, Yanzhi Hsu, Salah-Eddin Al-Batran. Eur J Cancer 2019
25
25

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Alexander Stein, Lisa Paschold, Joseph Tintelnot, Eray Goekkurt, Svenja-Sibylla Henkes, Donjete Simnica, Christoph Schultheiss, Edith Willscher, Marcus Bauer, Claudia Wickenhauser,[...]. JAMA Oncol 2022
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.